In The Media

Philadelphia Inquirer 2013-11-05 Sheller, P.C.’s representation of whistleblowers totals over $6 billion, with three of the top five pharmaceutical settlements in history: 2009: Pfizer $2.3 billion (Geodon) 2009: Eli Lilly & Co. $1.4

The Boston Globe 2013-08-22 Worcester’s UMass Memorial Medical Center has settled fraud charges with the attorney general in a whistleblower case alleging that it improperly sent bills for uninsured patients to a homeless

2014-12-19 The $2.2 Billion settlement with Johnson & Johnson Leads the Pack The Legal Intelligencer reported that the largest verdict and settlement award in Pennsylvania between August 2013 and August 2014 was handled
pharmalot,silverman,ed,risperdal,fda,petition

Lawyer Spars With FDA Over J&J Risperdal Court Documents by Ed Silverman, Pharmalot In an unusual tactic, an attorney is prodding the FDA to seek documents that purportedly detail side effects caused by

The Philadelphia Inquirer & “Fierce Pharma” 2013-07-10 The U.S. Food and Drug Administration is dragging its feet in addressing concerns that Johnson & Johnson’s antipsychotic drugs Risperdal and Invega are dangerous, a Philadelphia

The American Law Journal 2013-06-16 Attorney Stephen Sheller sparred with pharmaceutical defense attorney Hope Freiwald of Dechert law firm on the television program The American Law Journal. The attorneys, joined by Pharmalot author

2013-06-25 In a case involving a Philadelphia company, a divided U.S. Supreme Court ruled Monday that federal pharmaceutical laws preempt a person’s ability to sue in state court alleging that a generic drug

2013-05-17  The law firm of Sheller, P.C. announces the selection of six attorneys as Pennsylvania SuperLawyers® and one as Pennsylvania Rising Star for 2013. Stephen A. Sheller is once again honored for the

Temple University Office of University Communications 2013-02-13 Gift from Sheller Family Foundation builds on donors’ legacy of support for disenfranchised Stephen and Sandra Sheller, who have made their respective careers in law and

2012-12-31  A U.S. Appeals Court ruling that pitted free speech rights versus off-label promotion of pharmaceuticals has raised speculation that 2013 may usher in the sort of aggressive marketing by drug makers that